Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:secondary carboxamide
go back to main search page
Accession:CHEBI:140325 term browser browse the term
Definition:A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
Synonyms:related_synonym: Formula=CHNOR2;   SMILES=N(C(*)=O)(*)[H];   secondary carboxamides


show annotations for term's descendants           Sort by:
 
acalabrutinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crp C-reactive protein affects expression ISO acalabrutinib affects the expression of CRP protein CTD PMID:32503877 NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing
multiple interactions
affects metabolic processing
ISO CYP3A4 protein results in increased metabolism of acalabrutinib
Ketoconazole affects the reaction [CYP3A4 protein alternative form affects the metabolism of acalabrutinib]
CTD PMID:34153224 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Il6 interleukin 6 decreases expression ISO acalabrutinib results in decreased expression of IL6 protein CTD PMID:32503877 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
acetoacetyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 affects binding ISO acetoacetyl CoA binds to HSD17B2 protein CTD PMID:25526675 NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
JBrowse link
acetyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acly ATP citrate lyase increases abundance ISO ACLY protein results in increased abundance of Acetyl Coenzyme A CTD PMID:28077572 NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
JBrowse link
G App amyloid beta precursor protein affects localization
increases secretion
multiple interactions
ISO APP protein affects the localization of Acetyl Coenzyme A
Acetyl Coenzyme A results in increased secretion of APP protein modified form
Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A]
CTD PMID:16122837 PMID:22906069 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Crat carnitine O-acetyltransferase decreases activity EXP Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein CTD PMID:8075222 NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor decreases abundance
multiple interactions
ISO ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A
3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] CTD PMID:16122837 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Kat2b lysine acetyltransferase 2B affects binding ISO Acetyl Coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:6,562,525...6,667,064 JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator multiple interactions ISO METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A] CTD PMID:30213948 NCBI chr10:106,963,880...106,977,875
Ensembl chr10:106,963,880...106,977,869
JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions
affects binding
ISO [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein]
Acetyl Coenzyme A binds to NAT1 protein
CTD PMID:20545351 PMID:22835378 NCBI chr16:22,218,217...22,238,516 JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
acryloyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Echs1 enoyl-CoA hydratase, short chain 1 increases abundance ISO ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A CTD PMID:25125611 NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
JBrowse link
G Hibch 3-hydroxyisobutyryl-CoA hydrolase increases abundance ISO HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A CTD PMID:25125611 NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
JBrowse link
afatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egf epidermal growth factor multiple interactions ISO afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein]; afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein] CTD PMID:28787001 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egfr epidermal growth factor receptor decreases activity
decreases phosphorylation
ISO afatinib results in decreased activity of EGFR protein; afatinib results in decreased activity of EGFR protein mutant form
afatinib results in decreased phosphorylation of EGFR protein
CTD PMID:21322567 PMID:22242139 PMID:28787001 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 multiple interactions ISO afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein] CTD PMID:28787001 NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta decreases expression ISO afatinib results in decreased expression of IKBKB protein CTD PMID:22242139 NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 decreases phosphorylation ISO Afatinib results in decreased phosphorylation of IQGAP1 protein CTD PMID:33087447 NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO Afatinib inhibits the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA] CTD PMID:31944254 NCBI chr 1:196,864,375...196,896,475 JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO afatinib results in decreased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22242139 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Pou5f1 POU class 5 homeobox 1 decreases expression
multiple interactions
ISO afatinib results in decreased expression of POU5F1 protein
afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]
CTD PMID:28787001 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO afatinib results in decreased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22242139 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
arachidonoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
asperphenamate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ctsl cathepsin L multiple interactions ISO asperphenamate analog binds to and results in decreased activity of CTSL protein CTD PMID:30253340 NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
JBrowse link
G Ctss cathepsin S multiple interactions ISO asperphenamate analog binds to and results in decreased activity of CTSS protein CTD PMID:30253340 NCBI chr 2:183,089,192...183,114,483
Ensembl chr 2:183,086,437...183,114,483
JBrowse link
butyryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kat2b lysine acetyltransferase 2B affects binding ISO butyryl-coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:6,562,525...6,667,064 JBrowse link
carboxin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Anxa2 annexin A2 decreases expression ISO Carboxin results in decreased expression of ANXA2 mRNA CTD PMID:33512557 NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
JBrowse link
G Bbc3 Bcl-2 binding component 3 decreases expression ISO Carboxin results in decreased expression of BBC3 mRNA CTD PMID:33512557 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
copanlisib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO copanlisib results in decreased phosphorylation of AKT1 protein CTD PMID:31445927 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Fas Fas cell surface death receptor affects response to substance ISO copanlisib affects the susceptibility to FAS protein CTD PMID:31445927 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Tnf tumor necrosis factor increases response to substance ISO copanlisib results in increased susceptibility to TNF protein CTD PMID:31445927 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
dacomitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egfr epidermal growth factor receptor multiple interactions ISO dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] CTD PMID:27491023 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
decanoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein CTD PMID:25526675 NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839
JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
JBrowse link
glutaryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acot4 acyl-CoA thioesterase 4 affects hydrolysis ISO ACOT4 protein affects the hydrolysis of glutaryl-coenzyme A CTD PMID:16141203 NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
JBrowse link
G Acot8 acyl-CoA thioesterase 8 affects hydrolysis ISO ACOT8 protein affects the hydrolysis of glutaryl-coenzyme A CTD PMID:16141203 NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851
JBrowse link
glycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of glycolithocholic acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of glycolithocholic acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
JBrowse link
glycoursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Edn1 endothelin 1 decreases expression ISO glycoursodeoxycholic acid results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Slc4a2 solute carrier family 4 member 2 multiple interactions ISO [glycoursodeoxycholic acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form CTD PMID:18188457 NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
JBrowse link
G Tp53 tumor protein p53 multiple interactions EXP glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
glycyl-L-phenylalanine 2-naphthylamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nox1 NADPH oxidase 1 multiple interactions ISO 1-(3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]]; NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]] CTD PMID:24912985 NCBI chr  X:97,279,058...97,332,291
Ensembl chr  X:97,279,056...97,302,236
JBrowse link
GSK343 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Dicer1 dicer 1 ribonuclease III increases expression ISO GSK343 results in increased expression of DICER1 mRNA CTD PMID:25351418 NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit decreases activity ISO GSK343 results in decreased activity of EZH2 protein CTD PMID:23759589 PMID:24900432 NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
JBrowse link
hexanoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
JBrowse link
isobutyryl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kat2b lysine acetyltransferase 2B affects binding ISO isobutyryl-coenzyme A binds to KAT2B protein CTD PMID:28077572 NCBI chr 9:6,562,525...6,667,064 JBrowse link
lauroyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO lauroyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Hsdl2 hydroxysteroid dehydrogenase like 2 multiple interactions ISO [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein CTD PMID:25526675 NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839
JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase multiple interactions ISO [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein CTD PMID:25526675 NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
JBrowse link
LGK974 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased expression of BAK1 protein] CTD PMID:30205152 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Casp3 caspase 3 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein] CTD PMID:30205152 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in decreased expression of CCND1 protein] CTD PMID:30205152 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO LGK974 inhibits the reaction [Paraquat affects the localization of CTNNB1 protein]; LGK974 inhibits the reaction [Paraquat results in increased expression of and results in decreased phosphorylation of CTNNB1 protein] CTD PMID:30205152 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased transport of DIABLO protein] CTD PMID:30205152 NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
JBrowse link
G Htra2 HtrA serine peptidase 2 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased transport of HTRA2 protein] CTD PMID:30205152 NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO LGK974 inhibits the reaction [Paraquat results in increased cleavage of PARP1 protein] CTD PMID:30205152 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
malonyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mlycd malonyl-CoA decarboxylase multiple interactions ISO PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] CTD PMID:14641110 NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] CTD PMID:14641110 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
marimastat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Areg amphiregulin multiple interactions ISO marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of AREG protein] CTD PMID:15342401 NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
JBrowse link
G Grp gastrin releasing peptide multiple interactions ISO marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of AREG protein]; marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein] CTD PMID:15342401 NCBI chr18:59,388,679...59,402,061
Ensembl chr18:59,388,274...59,402,061
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions EXP marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK1 protein] CTD PMID:15574683 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions EXP marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK3 protein] CTD PMID:15574683 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK8 protein] CTD PMID:15574683 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO marimastat inhibits the reaction [Oxygen deficiency results in increased expression of MMP2 protein] CTD PMID:22340517 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein] CTD PMID:15342401 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
JBrowse link
methacrylyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Echs1 enoyl-CoA hydratase, short chain 1 increases abundance ISO ECHS1 gene mutant form results in increased abundance of methacrylyl-coenzyme A CTD PMID:25125611 NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
JBrowse link
G Hibch 3-hydroxyisobutyryl-CoA hydrolase increases abundance ISO HIBCH gene mutant form results in increased abundance of methacrylyl-coenzyme A CTD PMID:25125611 NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
JBrowse link
myristoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Dbi diazepam binding inhibitor, acyl-CoA binding protein affects binding ISO S-tetradecanoyl-coenzyme A binds to DBI protein CTD PMID:17044054 NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO S-tetradecanoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO S-tetradecanoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Drd2 dopamine receptor D2 affects response to substance
multiple interactions
affects binding
ISO
EXP
DRD2 promoter polymorphism affects the susceptibility to nemonapride
Cinnarizine inhibits the reaction [nemonapride binds to DRD2 protein]; Flunarizine inhibits the reaction [nemonapride binds to DRD2 protein]
CTD PMID:7503767 PMID:11505224 NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
JBrowse link
G Drd4 dopamine receptor D4 affects binding ISO nemonapride binds to DRD4 protein CTD PMID:31323226 NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
JBrowse link
N-(p-amylcinnamoyl)anthranilic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 multiple interactions ISO 4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein] CTD PMID:33309544 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions ISO 4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein] CTD PMID:33309544 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Slc13a2 solute carrier family 13 member 2 multiple interactions ISO [4-amylcinnamoylanthranilic acid results in decreased activity of SLC13A2 protein] which results in decreased susceptibility to diethylene glycol metabolite CTD PMID:21856646 NCBI chr10:63,291,813...63,319,127
Ensembl chr10:63,291,815...63,319,127
JBrowse link
G Trpm2 transient receptor potential cation channel, subfamily M, member 2 multiple interactions
decreases activity
ISO 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]
4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]
4-amylcinnamoylanthranilic acid results in decreased activity of TRPM2 protein
CTD PMID:18204483 PMID:30229906 PMID:33309544 NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
JBrowse link
N-acetyldopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mthfs methenyltetrahydrofolate synthetase affects binding ISO N-acetyldopamine binds to MTHFS protein CTD PMID:17055997 NCBI chr 8:89,729,498...89,801,998
Ensembl chr 8:89,729,508...89,799,089
JBrowse link
N-benzoyl-L-alanine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ncoa2 nuclear receptor coactivator 2 multiple interactions ISO N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein]; N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein] CTD PMID:31566444 NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
JBrowse link
G Thra thyroid hormone receptor alpha multiple interactions ISO N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein] CTD PMID:31566444 NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
JBrowse link
G Thrb thyroid hormone receptor beta multiple interactions
affects binding
ISO N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein]
N-benzoylalanine binds to THRB protein
CTD PMID:31566444 NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
JBrowse link
N-benzoylglycine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid] CTD PMID:30639138 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO hippuric acid inhibits the reaction [ABCC4 protein results in increased export of Methotrexate] CTD PMID:21483698 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO hippuric acid inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate] CTD PMID:21483698 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Col2a1 collagen type II alpha 1 chain multiple interactions EXP [COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of hippuric acid CTD PMID:24709313 NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
JBrowse link
G Slc10a1 solute carrier family 10 member 1 increases expression ISO hippuric acid results in increased expression of SLC10A1 mRNA CTD PMID:30639138 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
JBrowse link
N-Methylolacrylamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acsm1 acyl-CoA synthetase medium-chain family member 1 increases expression ISO N-methylolacrylamide results in increased expression of ACSM1 mRNA CTD PMID:17311802 NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495
JBrowse link
G Ces1d carboxylesterase 1D increases expression ISO N-methylolacrylamide results in increased expression of CES1 mRNA CTD PMID:17311802 NCBI chr19:13,873,490...13,912,035 JBrowse link
G Ephx1 epoxide hydrolase 1 decreases expression ISO N-methylolacrylamide results in decreased expression of EPHX1 mRNA CTD PMID:17311802 NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases activity ISO N-methylolacrylamide results in increased activity of NFE2L2 protein CTD PMID:30114225 PMID:30203046 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO N-methylolacrylamide results in increased expression of NQO1 mRNA CTD PMID:17311802 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases activity ISO N-methylolacrylamide results in decreased activity of STAT5B protein CTD PMID:30114225 NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
JBrowse link
N-oleoyldopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cnr1 cannabinoid receptor 1 multiple interactions EXP N-oleoyldopamine binds to and results in increased activity of CNR1 protein CTD PMID:12569099 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:27936102 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:27936102 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions
increases activity
ISO
EXP
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein] CTD PMID:12569099 PMID:15615864 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
JBrowse link
nilotinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A affects response to substance ISO ABCB1 protein affects the susceptibility to 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide CTD PMID:28623111 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Abcc10 ATP binding cassette subfamily C member 10 multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine] CTD PMID:19841739 NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 affects response to substance ISO ABCG2 protein affects the susceptibility to 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide CTD PMID:24954033 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions
decreases phosphorylation
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein]; [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide co-treated with arsenic trioxide] results in decreased phosphorylation of ABL1 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of ABL1 protein; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of ABL1 protein mutant form
CTD PMID:16849647 PMID:19878872 PMID:23883479 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
JBrowse link
G Acaca acetyl-CoA carboxylase alpha increases phosphorylation ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased phosphorylation of ACACA protein CTD PMID:23707608 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of ALDH1A2 mRNA CTD PMID:31711903 NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
JBrowse link
G Ap2m1 adaptor related protein complex 2 subunit mu 1 multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of AP2M1 mRNA CTD PMID:28786057 NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions
decreases expression
ISO arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of ATF6 protein] CTD PMID:23883479 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO
EXP
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of BAX protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of BAX mRNA]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of BAX protein]
CTD PMID:31593741 PMID:33710703 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of BCL2 protein CTD PMID:26549707 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcr BCR activator of RhoGEF and GTPase multiple interactions
decreases phosphorylation
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of BCR protein mutant form
CTD PMID:16849647 PMID:19878872 NCBI chr20:13,471,679...13,596,497
Ensembl chr20:13,471,668...13,597,016
JBrowse link
G C3 complement C3 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of C3 mRNA CTD PMID:32771489 NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases expression
increases activity
ISO
EXP
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of CASP3 mRNA]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of CASP3 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of CASP3 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of CASP3 protein]
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased activity of CASP3 protein
CTD PMID:23707608 PMID:23883479 PMID:26549707 PMID:31593741 PMID:32771489 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp7 caspase 7 increases activity
increases cleavage
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased activity of CASP7 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP7 protein
CTD PMID:23707608 PMID:23883479 NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp9 caspase 9 increases cleavage ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP9 protein CTD PMID:26549707 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cltc clathrin heavy chain multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of CLTC mRNA CTD PMID:28786057 NCBI chr10:71,517,661...71,574,591
Ensembl chr10:71,517,663...71,573,737
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein decreases phosphorylation
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of CRKL protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide co-treated with arsenic trioxide] results in decreased phosphorylation of CRKL protein
CTD PMID:19878872 PMID:23883479 NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of DDIT3 mRNA
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of DDIT3 mRNA]
CTD PMID:23883479 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Dnm2 dynamin 2 multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of DNM2 mRNA CTD PMID:28786057 NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
JBrowse link
G Edem1 ER degradation enhancing alpha-mannosidase like protein 1 increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of EDEM1 mRNA
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of EDEM1 mRNA]
CTD PMID:23883479 NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
JBrowse link
G Esr1 estrogen receptor 1 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of ESR1 protein CTD PMID:32771489 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Eya1 EYA transcriptional coactivator and phosphatase 1 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of EYA1 mRNA CTD PMID:31711903 NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
JBrowse link
G Fcer1g Fc fragment of IgE receptor Ig multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of FCER1G mRNA CTD PMID:28786057 NCBI chr13:83,649,447...83,654,215
Ensembl chr13:83,649,449...83,671,443
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS protein
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS protein]
CTD PMID:23883479 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Foxc2 forkhead box C2 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of FOXC2 mRNA CTD PMID:31711903 NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions
increases expression
ISO arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of GCLM mRNA] CTD PMID:23883479 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion
multiple interactions
ISO
EXP
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased secretion of GPT protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased activity of GPT protein]
CTD PMID:29655783 PMID:33710703 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased activity of GSR protein] CTD PMID:33710703 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Hdc histidine decarboxylase decreases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of HDC mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]
CTD PMID:16849647 NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased expression of HMOX1 mRNA] CTD PMID:33710703 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hoxb7 homeo box B7 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HOXB7 mRNA CTD PMID:31711903 NCBI chr10:81,252,616...81,256,034
Ensembl chr10:81,252,553...81,256,034
JBrowse link
G Hoxb9 homeo box B9 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HOXB9 mRNA CTD PMID:31711903 NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HSPA5 mRNA
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HSPA5 mRNA]
CTD PMID:23883479 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Il18 interleukin 18 multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of IL18 protein] CTD PMID:31593741 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO
EXP
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of IL1B protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of IL1B protein]
CTD PMID:31593741 PMID:33710703 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased expression of IL2 protein] CTD PMID:33710703 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of IL6 protein] CTD PMID:33710703 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of and results in increased phosphorylation of JUN protein; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN protein
CTD PMID:23883479 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB protein
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB protein]
CTD PMID:23883479 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased activity of KCNH2 protein CTD PMID:23707608 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
JBrowse link
G Meox1 mesenchyme homeobox 1 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of MEOX1 mRNA CTD PMID:31711903 NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
JBrowse link
G Mesp2 mesoderm posterior bHLH transcription factor 2 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of MESP2 mRNA CTD PMID:31711903 NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
JBrowse link
G Neurog2 neurogenin 2 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of NEUROG2 mRNA CTD PMID:31711903 NCBI chr 2:216,092,641...216,095,276
Ensembl chr 2:216,093,363...216,094,154
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased expression of NFE2L2 protein] CTD PMID:33710703 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased expression of NFKBIA mRNA] CTD PMID:33710703 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] CTD PMID:21473879 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Olig3 oligodendrocyte transcription factor 3 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of OLIG3 mRNA CTD PMID:31711903 NCBI chr 1:14,081,259...14,083,336
Ensembl chr 1:14,081,328...14,082,149
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein]
CTD PMID:26549707 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pax3 paired box 3 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of PAX3 mRNA CTD PMID:31711903 NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
JBrowse link
G Pax6 paired box 6 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of PAX6 mRNA CTD PMID:31711903 NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of RELA protein] CTD PMID:31593741 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Sacs sacsin molecular chaperone increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of SACS mRNA CTD PMID:29901742 NCBI chr15:35,285,783...35,370,335
Ensembl chr15:35,285,782...35,370,335
JBrowse link
G Sec24b SEC24 homolog B, COPII coat complex component multiple interactions ISO [arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of SEC24B mRNA CTD PMID:28786057 NCBI chr 2:218,562,670...218,632,753
Ensembl chr 2:218,562,676...218,632,699
JBrowse link
G Tcf15 transcription factor 15 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of TCF15 mRNA CTD PMID:31711903 NCBI chr 3:140,638,984...140,644,766
Ensembl chr 3:140,638,984...140,644,766
JBrowse link
G Tff1 trefoil factor 1 decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of TFF1 mRNA CTD PMID:32771489 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TGFB1 mRNA] CTD PMID:21473879 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP
ISO
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of TNF protein]
CTD PMID:21473879 PMID:31593741 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfsf12 TNF superfamily member 12 multiple interactions ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of TNFSF12 protein] CTD PMID:31593741 NCBI chr10:54,403,870...54,413,213
Ensembl chr10:54,403,870...54,413,213
JBrowse link
G Tp53 tumor protein p53 increases secretion ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased secretion of TP53 protein CTD PMID:29370077 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 decreases activity ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased activity of UGT1A1 protein CTD PMID:26875642 NCBI chr 9:88,801,344...88,808,465 JBrowse link
G Uncx UNC homeobox decreases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of UNCX mRNA CTD PMID:31711903 NCBI chr12:15,092,779...15,097,300
Ensembl chr12:15,092,784...15,097,300
JBrowse link
G Xbp1 X-box binding protein 1 increases expression ISO 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of XBP1 mRNA alternative form CTD PMID:23883479 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
JBrowse link
oleoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO oleoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO oleoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO oleoyl-coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
osimertinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein CTD PMID:30145802 PMID:30623574 PMID:30993382 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
ISO [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; Vitamin E inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form] CTD PMID:28237877 PMID:31916386 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions
decreases response to substance
ISO CAT protein inhibits the reaction [osimertinib results in increased abundance of Hydrogen Peroxide]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CAT protein results in decreased susceptibility to osimertinib
CTD PMID:28237877 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions ISO osimertinib inhibits the reaction [Dronabinol results in decreased expression of and results in decreased activity of CFTR protein] CTD PMID:29928919 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
JBrowse link
G Egf epidermal growth factor multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein] CTD PMID:30623574 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases activity
ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]; osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of EGFR protein
osimertinib results in decreased activity of EGFR protein
CTD PMID:28237877 PMID:30145802 PMID:30623574 PMID:30993382 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO osimertinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Il6 interleukin 6 multiple interactions ISO osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein] CTD PMID:30623574 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK1 protein CTD PMID:29928919 PMID:30623574 PMID:30993382 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK3 protein CTD PMID:29928919 PMID:30623574 PMID:30993382 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [ginsenoside Rg3 co-treated with osimertinib] results in decreased expression of MKI67 protein CTD PMID:31916386 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases expression
increases cleavage
multiple interactions
ISO osimertinib results in increased expression of PARP1 protein modified form
osimertinib results in increased cleavage of PARP1 protein
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; [TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]; Vitamin E inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CTD PMID:28237877 PMID:30171258 PMID:31916386 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Sqstm1 sequestosome 1 decreases expression ISO osimertinib results in decreased expression of SQSTM1 protein CTD PMID:30145802 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of STAT3 protein] CTD PMID:30623574 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases response to substance
multiple interactions
affects response to substance
ISO TWIST1 protein results in decreased susceptibility to osimertinib
[TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]
TWIST1 protein affects the susceptibility to osimertinib
CTD PMID:30171258 PMID:30993382 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
JBrowse link
p-aminohippuric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca8 ATP binding cassette subfamily A member 8 affects transport ISO ABCA8 protein affects the transport of p-Aminohippuric Acid CTD PMID:12379217 NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
JBrowse link
G Col2a1 collagen type II alpha 1 chain multiple interactions EXP [COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of p-Aminohippuric Acid CTD PMID:24709313 NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
JBrowse link
G Slc17a3 solute carrier family 17 member 3 affects transport ISO SLC17A3 gene SNP affects the transport of p-Aminohippuric Acid CTD PMID:21282933 NCBI chr17:41,270,804...41,300,132
Ensembl chr17:41,270,812...41,295,256
JBrowse link
G Slc22a12 solute carrier family 22 member 12 multiple interactions
increases uptake
ISO Barium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Diethyl Pyrocarbonate inhibits the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Ouabain promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Potassium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid] CTD PMID:15284287 NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO p-Aminohippuric Acid inhibits the reaction [SLC22A2 protein results in increased uptake of Cimetidine] CTD PMID:15496291 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc22a20 solute carrier family 22 member 20 multiple interactions ISO p-Aminohippuric Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate] CTD PMID:16478971 NCBI chr 1:203,257,374...203,273,848
Ensembl chr 1:203,257,374...203,273,822
JBrowse link
G Slc22a6 solute carrier family 22 member 6 affects transport
increases import
increases uptake
multiple interactions
increases export
increases secretion
ISO
EXP
SLC22A6 protein affects the transport of p-Aminohippuric Acid
SLC22A6 protein results in increased import of p-Aminohippuric Acid
SLC22A6 protein results in increased uptake of p-Aminohippuric Acid; SLC22A6 results in increased uptake of p-Aminohippuric Acid
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; 9-((2-phosphonylmethoxy)ethyl)guanine analog inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; adefovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Amitriptyline inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I inhibits the reaction [SLC22A6 results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid]; bis(4-hydroxyphenyl)sulfone inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; bisphenol A promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; bisphenol F promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefaclor inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefdinir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefotiam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Ceftibuten inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Ceftizoxime inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cephaloridine inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Chlorides promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; chlorpyrifos-methyl inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cimetidine inhibits the reaction [SLC22A6 protein affects the transport of p-Aminohippuric Acid]; cyazofamid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Diazepam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Fenitrothion inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Fluorescein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Glutarates promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; glutaric acid promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid]; Malathion inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Mianserin inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased susceptibility to [mercuric oxide co-treated with Acetylcysteine]]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased transport of 2-amino-3-(2-amino-2-carboxyethylsulfanyl-mercuricsulfanyl)-propionic acid analog]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased transport of 2-amino-3-(2-amino-2-carboxyethylsulfanyl-mercuricsulfanyl)-propionic acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of 2,4-Dichlorophenoxyacetic Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Cimetidine]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Uric Acid]; Penicillin G inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; quercetin 3'-sulfate inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Quercetin inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Resveratrol inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; rhein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; rhein metabolite inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Sulfobromophthalein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Tenofovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; Triazolam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol metabolite inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol metabolite promotes the reaction [SLC22A6 protein results in increased secretion of p-Aminohippuric Acid]; Unithiol promotes the reaction [SLC22A6 protein results in increased secretion of p-Aminohippuric Acid]
p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of ochratoxin A]; perfluoro-n-heptanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; perfluorohexanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; perfluorooctanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]
CTD PMID:10336520 PMID:11602689 PMID:12472777 PMID:12606766 PMID:15200431 More... NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
JBrowse link
G Slc22a7 solute carrier family 22 member 7 increases uptake ISO SLC22A7 protein results in increased uptake of p-Aminohippuric Acid CTD PMID:12065749 PMID:15901346 PMID:21256917 NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
JBrowse link
G Slc22a8 solute carrier family 22 member 8 multiple interactions
increases uptake
affects transport
increases export
ISO
EXP
Cimetidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Enalapril inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Ibuprofen inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; tenoxicam inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]
SLC22A8 protein affects the transport of p-Aminohippuric Acid
SLC22A8 results in increased export of p-Aminohippuric Acid
aristolochic acid I promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid]; estrone sulfate promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid]
p-Aminohippuric Acid inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]
CTD PMID:10224140 PMID:11306713 PMID:15100168 PMID:15319347 PMID:16098483 More... NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
JBrowse link
palmitoyl ethanolamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A increases export ISO ABCB1 protein results in increased export of palmidrol CTD PMID:30102254 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Apob apolipoprotein B affects folding ISO palmidrol affects the folding of APOB protein CTD PMID:16115474 NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) multiple interactions ISO [palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] CTD PMID:31054246 NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
JBrowse link
G Aqp4 aquaporin 4 affects expression ISO palmidrol affects the expression of AQP4 mRNA CTD PMID:31054246 NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
JBrowse link
G Cldn3 claudin 3 multiple interactions
decreases expression
ISO [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA
palmidrol results in decreased expression of CLDN3 mRNA
CTD PMID:31054246 NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
JBrowse link
G Cldn5 claudin 5 decreases expression ISO palmidrol results in decreased expression of CLDN5 mRNA CTD PMID:31054246 NCBI chr11:82,212,822...82,214,248 JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions EXP [rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to palmidrol analog CTD PMID:17558434 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
JBrowse link
G Cnr2 cannabinoid receptor 2 affects binding
multiple interactions
ISO
EXP
palmidrol binds to CNR2 protein
[SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog
CTD PMID:10617657 PMID:10688601 PMID:17558434 NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions EXP palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of GSTA1 protein] CTD PMID:26474837 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Ifng interferon gamma multiple interactions ISO [palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] CTD PMID:31054246 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Lcn2 lipocalin 2 multiple interactions EXP palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of LCN2 protein] CTD PMID:26474837 NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions
affects localization
EXP [MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]
palmidrol affects the localization of PPARA protein
CTD PMID:17558434 PMID:31787870 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] CTD PMID:31054246 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions ISO palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA] CTD PMID:31054246 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
JBrowse link
palmitoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acox1 acyl-CoA oxidase 1 increases metabolic processing
multiple interactions
ISO ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A
[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]
CTD PMID:10497882 NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
JBrowse link
G Ces1d carboxylesterase 1D increases hydrolysis EXP CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A CTD PMID:8611161 NCBI chr19:13,873,490...13,912,035 JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions EXP valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A] CTD PMID:19854160 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Dgat1 diacylglycerol O-acyltransferase 1 multiple interactions ISO DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A] CTD PMID:16214399 NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha decreases expression ISO Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein CTD PMID:17992261 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein
Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
CTD PMID:11139385 PMID:18812576 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Shbg sex hormone binding globulin decreases expression ISO Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein CTD PMID:17992261 NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
JBrowse link
PD 168393 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein] CTD PMID:25398788 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein] CTD PMID:25398788 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of BAD protein CTD PMID:16413505 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein CTD PMID:16413505 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression
ISO PD168393 results in increased expression of and results in increased secretion of CCL2 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA] CTD PMID:21967610 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of CDKN1A protein CTD PMID:16413505 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions
increases expression
ISO acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; PD168393 results in increased expression of and results in increased secretion of CXCL10 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein] CTD PMID:21967610 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [PD168393 co-treated with Paclitaxel] affects the localization of CYCS protein CTD PMID:16413505 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
JBrowse link
G Egfr epidermal growth factor receptor affects localization
multiple interactions
decreases phosphorylation
ISO
EXP
PD168393 affects the localization of EGFR protein; PD168393 affects the localization of EGFR protein modified form
PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]
[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of EGFR protein]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]
PD168393 results in decreased phosphorylation of EGFR protein
CTD PMID:16413505 PMID:21967610 PMID:23527233 PMID:25398788 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of JAK3 protein] CTD PMID:16778083 NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK1 protein]; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK1 protein]
PD168393 results in decreased phosphorylation of MAPK1 protein
CTD PMID:16413505 PMID:16778083 PMID:23527233 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK3 protein]; PD168393 inhibits the reaction [resveratrol results in increased phosphorylation of MAPK3 protein]
PD168393 results in decreased phosphorylation of MAPK3 protein
CTD PMID:16413505 PMID:16778083 PMID:23527233 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK8 protein] CTD PMID:16778083 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased expression of MMP3 mRNA] CTD PMID:29535049 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA] CTD PMID:25398788 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP PD168393 inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein] CTD PMID:22031849 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein] CTD PMID:21967610 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]] CTD PMID:25398788 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of TP53 protein CTD PMID:16413505 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
pepstatin A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO pepstatin inhibits the reaction [AKT1 protein modified form results in increased susceptibility to Etoposide] CTD PMID:17699715 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] CTD PMID:16850161 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions EXP pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein]; pepstatin inhibits the reaction [thallium nitrate analog results in increased cleavage of BID protein] CTD PMID:22669516 PMID:28378122 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Casp3 caspase 3 multiple interactions EXP
ISO
pepstatin affects the reaction [thallium nitrate results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; pepstatin inhibits the reaction [thallium nitrate analog results in increased activity of CASP3 protein]
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein modified form]
CTD PMID:22669516 PMID:26853465 PMID:28378122 PMID:31226464 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 multiple interactions EXP pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] CTD PMID:28378122 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein]
pepstatin inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein modified form]
CTD PMID:28378122 PMID:31226464 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ctsb cathepsin B multiple interactions ISO [aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; [CA 074 methyl ester co-treated with pepstatin] results in decreased expression of CTSB protein CTD PMID:32186374 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
JBrowse link
G Ctsd cathepsin D multiple interactions
decreases activity
ISO
EXP
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein; [CA 074 methyl ester co-treated with pepstatin] results in decreased expression of CTSD protein; pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form]
pepstatin results in decreased activity of CTSD protein
CTD PMID:6497855 PMID:11423908 PMID:16850161 PMID:32186374 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Faslg Fas ligand multiple interactions EXP pepstatin inhibits the reaction [manganese chloride results in increased expression of FASLG protein] CTD PMID:28378122 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Hmga1 high mobility group AT-hook 1 multiple interactions ISO pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of HMGA1 mRNA] CTD PMID:20660070 NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
JBrowse link
G Inhba inhibin subunit beta A multiple interactions ISO pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA] CTD PMID:20660070 NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 multiple interactions ISO [aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein; [CA 074 methyl ester co-treated with pepstatin] results in increased expression of LAMP2 protein CTD PMID:32186374 NCBI chr  X:117,173,097...117,222,090
Ensembl chr  X:117,057,606...117,260,522
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; pepstatin promotes the reaction [BO-1051 results in increased expression of MAP1LC3B protein modified form] CTD PMID:21184746 PMID:27635674 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein] CTD PMID:16850161 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [CA 074 methyl ester co-treated with pepstatin] results in increased expression of SQSTM1 protein
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein
CTD PMID:32186374 PMID:32773031 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Stc1 stanniocalcin 1 multiple interactions ISO pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC1 mRNA] CTD PMID:20660070 NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264
JBrowse link
G Tnfaip6 TNF alpha induced protein 6 multiple interactions ISO pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFAIP6 mRNA] CTD PMID:20660070 NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
JBrowse link
G Tomm20 translocase of outer mitochondrial membrane 20 multiple interactions ISO pepstatin inhibits the reaction [Doxorubicin results in decreased expression of TOMM20 protein] CTD PMID:31226464 NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
JBrowse link
PHA-665752 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of AKT1 protein] CTD PMID:22040890 PMID:25002221 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of BCL2L1 protein CTD PMID:20661229 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein
Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein]
CTD PMID:20661229 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in decreased expression of CAT protein] CTD PMID:22040890 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Egfr epidermal growth factor receptor decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]
CTD PMID:21266357 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] CTD PMID:20661229 PMID:21812414 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein] CTD PMID:21266357 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases activity
increases mutagenesis
decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased activity of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of and results in decreased activity of MET protein; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]
CTD PMID:20661229 PMID:21106725 PMID:21266357 PMID:21812414 PMID:25002221 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
CTD PMID:21266357 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
increases response to substance
increases expression
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] which results in increased expression of TGFA mRNA; Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA mRNA; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA protein
CTD PMID:21266357 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of XIAP protein CTD PMID:20661229 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link
phenylacetylglycine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Col2a1 collagen type II alpha 1 chain multiple interactions EXP [COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine] CTD PMID:24709313 NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
JBrowse link
salicyluric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin multiple interactions ISO ALB protein binds to and affects the transport of salicylurate CTD PMID:8831264 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
salubrinal term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions EXP salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of FN1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of SREBF1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; salubrinal inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein] CTD PMID:25398788 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP salubrinal inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein] CTD PMID:25398788 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO salubrinal results in increased expression of ATF3 mRNA CTD PMID:23690448 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
ISO
EXP
[salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein; salubrinal inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of ATF4 protein]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF4 protein]]; salubrinal promotes the reaction [Quercetin results in increased expression of ATF4 protein]
salubrinal promotes the reaction [Thapsigargin results in increased expression of ATF4 protein]; salubrinal promotes the reaction [Tunicamycin results in increased expression of ATF4 protein]
salubrinal promotes the reaction [Cisplatin results in increased expression of ATF4 protein]
salubrinal results in increased expression of ATF4 protein
CTD PMID:21616140 PMID:21809093 PMID:23690448 PMID:25611565 PMID:25950987 More... NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atf6 activating transcription factor 6 increases expression ISO salubrinal results in increased expression of ATF6 mRNA CTD PMID:23958496 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO
EXP
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased expression of BAX protein]]; salubrinal promotes the reaction [Cisplatin results in increased expression of BAX protein]
salubrinal inhibits the reaction [cadmium acetate results in increased expression of BAX protein]
CTD PMID:21616140 PMID:30605698 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO
EXP
salubrinal inhibits the reaction [alpha-Tocopherol analog results in decreased expression of BCL2 protein]; salubrinal inhibits the reaction [Quercetin results in decreased expression of BCL2 protein]
salubrinal inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein]
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]]; salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]
CTD PMID:20686688 PMID:21616140 PMID:25611565 PMID:30605698 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Becn1 beclin 1 multiple interactions ISO salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased expression of BECN1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased expression of BECN1 protein] CTD PMID:20929985 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
JBrowse link
G Calr calreticulin multiple interactions ISO [salubrinal results in decreased activity of [PPP1CC protein binds to PPP1R15A protein]] which affects the localization of CALR protein CTD PMID:17187072 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
JBrowse link
G Casp12 caspase 12 multiple interactions ISO
EXP
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP12 protein]]; salubrinal inhibits the reaction [decamethrin results in increased expression of CASP12 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of CASP12 mRNA]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP12 protein]
salubrinal inhibits the reaction [arsenite results in increased activity of CASP12 protein]; salubrinal inhibits the reaction [Rotenone results in increased cleavage of CASP12 protein]
CTD PMID:18226606 PMID:21616140 PMID:25428620 PMID:26446018 PMID:31841155 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
JBrowse link
G Casp3 caspase 3 multiple interactions ISO
EXP
salubrinal inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]; salubrinal inhibits the reaction [MAP3K5 protein results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Paraquat results in increased activity of CASP3 protein]
salubrinal inhibits the reaction [Rotenone results in increased expression of CASP3 mRNA]; salubrinal inhibits the reaction [Tetrachlorodibenzodioxin results in increased cleavage of CASP3 protein]
salubrinal inhibits the reaction [decamethrin results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [decamethrin results in increased cleavage of and results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of CASP3 mRNA]; salubrinal promotes the reaction [Cisplatin results in increased activity of CASP3 protein]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]
CTD PMID:19735704 PMID:20929985 PMID:21616140 PMID:21809093 PMID:24932542 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions ISO Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein] CTD PMID:21616140 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in increased expression of CCL2 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA] CTD PMID:23958496 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in increased expression of CCL5 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA] CTD PMID:23958496 NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in decreased expression of CDH1 protein] CTD PMID:22155090 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions EXP salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA] CTD PMID:23690541 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions EXP salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA] CTD PMID:23690541 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO salubrinal inhibits the reaction [MAP3K5 protein affects the localization of CYCS protein]; salubrinal inhibits the reaction [Paraquat affects the localization of CYCS protein] CTD PMID:20929985 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
decreases expression
increases expression
ISO
EXP
EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]]; salubrinal inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Cadmium Chloride results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Quercetin results in increased expression of DDIT3 protein]
salubrinal results in decreased expression of DDIT3 protein
salubrinal inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Thapsigargin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Tunicamycin results in increased expression of DDIT3 protein]
salubrinal results in increased expression of DDIT3 mRNA
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased expression of DDIT3 protein]]; salubrinal inhibits the reaction [alpha-naphthoflavone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Cisplatin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Cyclosporine results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Tacrolimus results in increased expression of DDIT3 protein]
CTD PMID:18305250 PMID:19735704 PMID:20686688 PMID:21616140 PMID:21809093 More... NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Edem1 ER degradation enhancing alpha-mannosidase like protein 1 multiple interactions ISO salubrinal inhibits the reaction [Paraquat results in increased expression of EDEM1 protein] CTD PMID:19735704 NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions
increases expression
increases phosphorylation
affects phosphorylation
ISO
EXP
salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of EIF2A protein]; salubrinal inhibits the reaction [EIF2A protein results in decreased susceptibility to nonivamide]
salubrinal results in increased expression of EIF2A protein modified form
salubrinal results in increased phosphorylation of EIF2A protein
salubrinal affects the phosphorylation of EIF2A protein
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased phosphorylation of EIF2A protein]]; salubrinal promotes the reaction [Cisplatin results in increased phosphorylation of EIF2A protein]
CTD PMID:17332266 PMID:17418795 PMID:18305250 PMID:18684481 PMID:20071420 More... NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases expression
increases phosphorylation
multiple interactions
ISO
EXP
salubrinal results in increased expression of EIF2S1 protein modified form
salubrinal results in increased phosphorylation of EIF2S1 protein
salubrinal inhibits the reaction [Rotenone results in decreased phosphorylation of EIF2S1 protein]
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK1 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK3 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK8 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK9 protein; salubrinal inhibits the reaction [cadmium acetate results in increased expression of EIF2S1 protein modified form]; salubrinal inhibits the reaction [Rotenone results in decreased phosphorylation of EIF2S1 protein]; salubrinal inhibits the reaction [Thapsigargin results in increased expression of EIF2S1 mRNA]; salubrinal inhibits the reaction [Tunicamycin results in increased expression of EIF2S1 mRNA]; salubrinal promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of EIF2S1 protein]
[salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein; [salubrinal results in decreased activity of EIF2S1 protein] which results in decreased susceptibility to decamethrin; EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]]; EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased phosphorylation of EIF2S1 protein]]; salubrinal promotes the reaction [Cadmium Chloride results in increased phosphorylation of EIF2S1 protein]; salubrinal promotes the reaction [Paraquat results in increased expression of EIF2S1 protein modified form]; salubrinal promotes the reaction [Quercetin results in increased phosphorylation of EIF2S1 protein]; salubrinal results in increased phosphorylation of and results in decreased activity of EIF2S1 protein
CTD PMID:21147958 PMID:21555338 PMID:21809093 PMID:23690448 PMID:24932542 More... NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
JBrowse link
G Epo erythropoietin multiple interactions ISO [salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein; [salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein CTD PMID:23690448 NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
JBrowse link
G Fn1 fibronectin 1 multiple interactions EXP salubrinal inhibits the reaction [AGT protein results in increased expression of FN1 protein] CTD PMID:25398788 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP salubrinal inhibits the reaction [Rotenone results in decreased activity of GSR protein] CTD PMID:26446018 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO salubrinal promotes the reaction [Cisplatin results in increased expression of HAVCR1 mRNA] CTD PMID:21616140 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hgf hepatocyte growth factor multiple interactions EXP salubrinal inhibits the reaction [Thapsigargin results in decreased expression of HGF mRNA]; salubrinal inhibits the reaction [Thapsigargin results in decreased expression of HGF protein]; salubrinal inhibits the reaction [Tunicamycin results in decreased expression of HGF mRNA]; salubrinal inhibits the reaction [Tunicamycin results in decreased expression of HGF protein] CTD PMID:28844859 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression
ISO
EXP
EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]
salubrinal inhibits the reaction [Rotenone results in increased expression of HSPA5 protein]
salubrinal results in increased expression of HSPA5 protein
salubrinal inhibits the reaction [Rotenone results in increased expression of HSPA5 protein]; salubrinal inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; salubrinal promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of HSPA5 protein]
CTD PMID:19735704 PMID:24932542 PMID:25428620 PMID:26446018 PMID:28844859 More... NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 affects response to substance
multiple interactions
ISO salubrinal affects the susceptibility to MAP3K5 protein
salubrinal affects the susceptibility to [Paraquat co-treated with MAP3K5 protein]; salubrinal inhibits the reaction [MAP3K5 protein affects the localization of CYCS protein]; salubrinal inhibits the reaction [MAP3K5 protein results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Paraquat results in increased phosphorylation of and results in increased activity of MAP3K5 protein]; salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased expression of BECN1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased expression of BECN1 protein]
CTD PMID:19735704 PMID:20929985 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP
salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein]
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK1 protein
CTD PMID:21147958 PMID:22155090 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO salubrinal inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK14 protein] CTD PMID:21809093 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO
EXP
salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein]
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK3 protein
CTD PMID:21147958 PMID:22155090 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP
ISO
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK8 protein
salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of MAPK8 protein]; salubrinal inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein]
CTD PMID:20686688 PMID:21147958 PMID:21809093 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO
EXP
salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of MAPK9 protein]
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK9 protein
CTD PMID:20686688 PMID:21147958 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
JBrowse link
G Myh3 myosin heavy chain 3 decreases expression ISO salubrinal results in decreased expression of MYH3 protein CTD PMID:29380555 NCBI chr10:51,770,177...51,793,994
Ensembl chr10:51,770,177...51,793,992
JBrowse link
G Myod1 myogenic differentiation 1 decreases expression ISO salubrinal results in decreased expression of MYOD1 protein CTD PMID:29380555 NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
JBrowse link
G Myog myogenin decreases expression ISO salubrinal results in decreased expression of MYOG protein CTD PMID:29380555 NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
JBrowse link
G Ngf nerve growth factor multiple interactions ISO salubrinal inhibits the reaction [decamethrin results in decreased expression of NGF protein] CTD PMID:31841155 NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
ISO Acetylcysteine inhibits the reaction [salubrinal results in increased expression of [Cisplatin results in increased expression of NOX4 protein]] CTD PMID:21616140 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO salubrinal inhibits the reaction [Cadmium Chloride results in increased cleavage of PARP1 protein]; salubrinal inhibits the reaction [Cyclosporine results in increased cleavage of PARP1 protein] CTD PMID:21809093 PMID:22155090 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Ppp1cc protein phosphatase 1 catalytic subunit gamma multiple interactions ISO [salubrinal results in decreased activity of [PPP1CC protein binds to PPP1R15A protein]] which affects the localization of CALR protein CTD PMID:17187072 NCBI chr12:34,383,072...34,400,553
Ensembl chr12:34,383,072...34,400,553
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A multiple interactions
increases expression
ISO [salubrinal results in decreased activity of [PPP1CC protein binds to PPP1R15A protein]] which affects the localization of CALR protein
salubrinal results in increased expression of PPP1R15A protein
CTD PMID:17187072 PMID:23690448 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
JBrowse link
G Slc38a2 solute carrier family 38, member 2 multiple interactions ISO salubrinal promotes the reaction [arsenic trioxide results in increased expression of SLC38A2 mRNA] CTD PMID:23892647 NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
JBrowse link
G Smad2 SMAD family member 2 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein] CTD PMID:22155090 NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased degradation of SQSTM1 protein] CTD PMID:20929985 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of SREBF1 mRNA] CTD PMID:25398788 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO salubrinal inhibits the reaction [Quercetin results in decreased phosphorylation of STAT3 protein] CTD PMID:25611565 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein] CTD PMID:25398788 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Th tyrosine hydroxylase multiple interactions EXP salubrinal inhibits the reaction [Rotenone results in decreased expression of TH protein] CTD PMID:26446018 NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO salubrinal inhibits the reaction [Cyclosporine results in decreased expression of TJP1 protein] CTD PMID:22155090 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
JBrowse link
G Trib3 tribbles pseudokinase 3 multiple interactions ISO salubrinal promotes the reaction [arsenic trioxide results in increased expression of TRIB3 mRNA] CTD PMID:23892647 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression
multiple interactions
EXP salubrinal results in increased expression of VEGFA mRNA
salubrinal promotes the reaction [Thapsigargin results in increased expression of VEGFA mRNA]
CTD PMID:28844859 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
SCH772984 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] CTD PMID:31706003 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adm adrenomedullin decreases secretion
multiple interactions
EXP SCH772984 results in decreased secretion of ADM protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of ADM protein]
CTD PMID:28087833 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
JBrowse link
G App amyloid beta precursor protein multiple interactions EXP SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein] CTD PMID:28087833 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of and results in increased expression of CREB1 protein]; SCH772984 results in decreased phosphorylation of and results in decreased expression of CREB1 protein CTD PMID:28087833 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein] CTD PMID:28087833 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 mRNA]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 protein] CTD PMID:31585129 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases secretion
EXP SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]
SCH772984 results in increased secretion of FGF2 protein
CTD PMID:28087833 NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [SCH772984 co-treated with bilobalide] inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]; SCH772984 inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]] CTD PMID:28087833 PMID:32319158 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Gpr4 G protein-coupled receptor 4 multiple interactions ISO SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein] CTD PMID:33161135 NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599
JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions EXP SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr 1:201,581,480...201,601,580
Ensembl chr 1:201,581,480...201,601,582
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of HSPA1A protein] CTD PMID:28087833
G Il6 interleukin 6 multiple interactions EXP SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of IL6 protein] CTD PMID:28087833 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of JUN protein] CTD PMID:28087833 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 increases phosphorylation EXP SCH772984 results in increased phosphorylation of MAP2K1 protein CTD PMID:28087833 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 increases phosphorylation EXP SCH772984 results in increased phosphorylation of MAP2K2 protein CTD PMID:28087833 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions
decreases expression
decreases activity
EXP
ISO
SCH772984 results in increased phosphorylation of MAPK1 protein
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK1 protein]
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK1 protein]
SCH772984 results in decreased expression of MAPK1 protein
SCH772984 results in decreased activity of MAPK1 protein
CTD PMID:28087833 PMID:29925859 PMID:32822868 PMID:33161135 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases activity
decreases expression
multiple interactions
increases phosphorylation
EXP
ISO
SCH772984 results in decreased activity of MAPK3 protein
SCH772984 results in decreased expression of MAPK3 protein
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK3 protein]
SCH772984 results in increased phosphorylation of MAPK3 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK3 protein]
CTD PMID:28087833 PMID:29925859 PMID:32822868 PMID:33161135 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 decreases expression
multiple interactions
EXP SCH772984 results in decreased expression of MAPK8 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK8 protein]
CTD PMID:28087833 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of NFE2L2 protein] CTD PMID:28087833 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions EXP SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of and results in increased phosphorylation of SP1 protein]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of SP1 mRNA] CTD PMID:31585129 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
JBrowse link
G Spi1 Spi-1 proto-oncogene multiple interactions ISO SCH772984 inhibits the reaction [saikosaponin D results in increased expression of SPI1 protein] CTD PMID:32822868 NCBI chr 3:77,059,744...77,093,730
Ensembl chr 3:77,073,012...77,092,393
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Vim vimentin multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
sivelestat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Elane elastase, neutrophil expressed decreases activity ISO sivelestat results in decreased activity of ELANE protein CTD PMID:19088179 NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
JBrowse link
SR 144528 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO SR 144528 inhibits the reaction [celastrol inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]] CTD PMID:29789558 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased phosphorylation of AKT1 protein]; SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of AKT1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of AKT1 protein] CTD PMID:12834810 PMID:30733293 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of ATF4 mRNA] CTD PMID:31054322 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of ATF6 mRNA] CTD PMID:31054322 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
JBrowse link
G Casp3 caspase 3 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased activity of CASP3 protein] CTD PMID:16818634 PMID:16818650 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 protein]] CTD PMID:10218491 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased expression of CDK1 protein] CTD PMID:16818634 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cnp 2',3'-cyclic nucleotide 3' phosphodiesterase multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of CNP protein] CTD PMID:32956517 NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions ISO SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] CTD PMID:11891798 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
JBrowse link
G Cnr2 cannabinoid receptor 2 affects binding
multiple interactions
ISO
EXP
SR 144528 binds to CNR2 protein
SR 144528 binds to and results in decreased activity of CNR2 protein
[SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog; SR 144528 binds to and results in decreased activity of CNR2 protein; SR 144528 inhibits the reaction [[3-(1,1-dimethyl-heptyl)-1-9-dihydroxy-benzo(c)chromen-6-one binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [[AM 1241 binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [CNR2 protein affects the susceptibility to Dronabinol]
[SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; SR 144528 binds to and results in decreased activity of CNR2 protein; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 protein]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CXCL8 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CXCL8 protein]]; SR 144528 inhibits the reaction [Dronabinol inhibits the reaction [ERBB2 protein binds to CNR2 protein]]
CTD PMID:10218491 PMID:10617657 PMID:10688601 PMID:12509806 PMID:15115777 More... NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of DDIT3 mRNA] CTD PMID:31054322 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol inhibits the reaction [ERBB2 protein binds to CNR2 protein]]; SR 144528 inhibits the reaction [Dronabinol inhibits the reaction [ERBB2 protein binds to ERBB2 protein]]; SR 144528 inhibits the reaction [Dronabinol results in decreased expression of and affects the phosphorylation of ERBB2 protein] CTD PMID:30733293 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO SR 144528 inhibits the reaction [celastrol inhibits the reaction [Folic Acid results in increased expression of FN1 protein]] CTD PMID:29789558 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Gata3 GATA binding protein 3 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of GATA3 mRNA] CTD PMID:14741435 NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of HSPA5 mRNA] CTD PMID:31054322 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Ifng interferon gamma multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased expression of IFNG mRNA]; SR 144528 inhibits the reaction [Dronabinol results in decreased expression of IFNG protein] CTD PMID:12446015 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il10 interleukin 10 multiple interactions ISO SR 144528 inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]] CTD PMID:15821753 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il12b interleukin 12B multiple interactions ISO SR 144528 inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]] CTD PMID:15821753 NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; SR 144528 inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]] CTD PMID:15748152 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased expression of IL2 mRNA] CTD PMID:12446015 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il4 interleukin 4 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of IL4 mRNA]; SR 144528 inhibits the reaction [Dronabinol results in increased expression of IL4 protein] CTD PMID:12446015 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il5 interleukin 5 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of IL5 mRNA] CTD PMID:12446015 NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
JBrowse link
G Irf1 interferon regulatory factor 1 multiple interactions ISO SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of IRF1 protein]] CTD PMID:28624443 NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
JBrowse link
G Mag myelin-associated glycoprotein multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of MAG protein] CTD PMID:32956517 NCBI chr 1:86,148,227...86,163,726
Ensembl chr 1:86,148,228...86,163,656
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased phosphorylation of MAPK1 protein]; SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of MAPK1 protein] CTD PMID:12834810 PMID:30733293 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in decreased phosphorylation of MAPK3 protein]; SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of MAPK3 protein] CTD PMID:12834810 PMID:30733293 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK8 protein] CTD PMID:24184660 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK9 protein] CTD PMID:24184660 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
JBrowse link
G Mog myelin oligodendrocyte glycoprotein multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of MOG protein] CTD PMID:32956517 NCBI chr20:1,513,137...1,523,473
Ensembl chr20:1,513,239...1,523,474
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] CTD PMID:15748152 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of NUPR1 mRNA] CTD PMID:16818650 NCBI chr 1:181,213,292...181,215,327 JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased localization of RAF1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased localization of RAF1 protein] CTD PMID:12834810 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO SR 144528 inhibits the reaction [Dronabinol results in increased expression of TGFB1 protein] CTD PMID:11779138 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of IRF1 protein]]; SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] CTD PMID:28624443 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] CTD PMID:28624443 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO SR 144528 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of and results in decreased secretion of VEGFA protein] CTD PMID:15313899 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO [Rimonabant co-treated with SR 144528] inhibits the reaction [Dronabinol results in increased expression of XBP1 mRNA alternative form] CTD PMID:31054322 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
JBrowse link
stearoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO stearoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein CTD PMID:10542059 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO stearoyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO stearoyl-coenzyme A binds to and results in increased activity of PPARG protein CTD PMID:11139385 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
succinyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acot4 acyl-CoA thioesterase 4 affects hydrolysis ISO ACOT4 protein affects the hydrolysis of succinyl-coenzyme A CTD PMID:16141203 NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
JBrowse link
sulfoglycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc10a1 solute carrier family 10 member 1 increases uptake ISO SLC10A1 protein results in increased uptake of sulfolithocholylglycine CTD PMID:29024779 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
JBrowse link
suramin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Calca calcitonin-related polypeptide alpha multiple interactions EXP Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]] CTD PMID:12044622 NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
JBrowse link
G Casp1 caspase 1 multiple interactions EXP Suramin inhibits the reaction [Glucose results in increased activity of CASP1 protein] CTD PMID:21832250 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
JBrowse link
G Casp3 caspase 3 multiple interactions ISO Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3]; Suramin inhibits the reaction [Clodronic Acid results in increased expression of CASP3] CTD PMID:19448140 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Chrna7 cholinergic receptor nicotinic alpha 7 subunit increases expression ISO Suramin results in increased expression of CHRNA7 protein CTD PMID:23516405 NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of CREB1 protein] CTD PMID:18612546 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity ISO Suramin results in decreased activity of CYP1A2 protein CTD PMID:11124226 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO Suramin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] CTD PMID:22167199 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 decreases activity ISO Suramin results in decreased activity of CYP2C19 protein CTD PMID:11124226 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions EXP Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] CTD PMID:9710602 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Fgf2 fibroblast growth factor 2 increases expression ISO Suramin results in increased expression of FGF2 CTD PMID:8394679 NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
JBrowse link
G Fgf5 fibroblast growth factor 5 increases expression ISO Suramin results in increased expression of FGF5 CTD PMID:8394679 NCBI chr14:11,325,334...11,346,570
Ensembl chr14:11,325,334...11,345,997
JBrowse link
G Fgf7 fibroblast growth factor 7 affects localization
multiple interactions
ISO Suramin affects the localization of FGF7 protein
Suramin inhibits the reaction [FGF7 protein binds to FGFR2 protein]
CTD PMID:15733146 NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
JBrowse link
G Fgfr2 fibroblast growth factor receptor 2 multiple interactions ISO Suramin inhibits the reaction [FGF7 protein binds to FGFR2 protein] CTD PMID:15733146 NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
JBrowse link
G Fmr1 FMRP translational regulator 1 multiple interactions ISO Suramin inhibits the reaction [Poly I-C results in decreased expression of FMR1 protein] CTD PMID:23516405 NCBI chr  X:147,240,239...147,278,057
Ensembl chr  X:147,240,301...147,278,050
JBrowse link
G Gusb glucuronidase, beta decreases activity EXP suramin decreases activity of beta-glucuronidase in rat spleen, kidney, and lung RGD PMID:2879381 RGD:42724461 NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
JBrowse link
G Hpgds hematopoietic prostaglandin D synthase decreases activity ISO Suramin results in decreased activity of HPGDS protein CTD PMID:25603235 NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases activity
ISO Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of IL10 protein]
Suramin results in decreased activity of IL10 protein
CTD PMID:15914193 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il12b interleukin 12B increases expression ISO Suramin results in increased expression of IL12B protein CTD PMID:15914193 NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il6 interleukin 6 multiple interactions ISO Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Silicon Dioxide analog results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein]
Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
CTD PMID:24793913 PMID:24849676 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Lmna lamin A/C multiple interactions ISO Suramin inhibits the reaction [LMNA protein binds to and results in increased activity of SIRT1 protein] CTD PMID:23217256 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK1 protein]
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein]
Suramin inhibits the reaction [2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein]
CTD PMID:8758915 PMID:9710602 PMID:14674888 PMID:15930183 PMID:18612546 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO
EXP
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK3 protein]
Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein]
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]
CTD PMID:9710602 PMID:14674888 PMID:15930183 PMID:18612546 PMID:23516405 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G P2rx1 purinergic receptor P2X 1 affects binding EXP Suramin binds to P2rx1 protein RGD PMID:12237343 RGD:727431 NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
JBrowse link
G P2rx2 purinergic receptor P2X 2 affects activity EXP suramin affects activity of rat P2x2 receptor in transfected glial cells RGD PMID:16388598 RGD:1642662 NCBI chr12:46,338,979...46,342,891
Ensembl chr12:46,339,549...46,342,891
JBrowse link
G P2rx3 purinergic receptor P2X 3 multiple interactions EXP Suramin inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein] CTD PMID:23666265 NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
JBrowse link
G P2rx5 purinergic receptor P2X 5 affects transport EXP Suramin affects transport ion flux of P2rx5 receptor RGD PMID:12237343 RGD:727431 NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423
JBrowse link
G P2rx7 purinergic receptor P2X 7 multiple interactions ISO Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RX7 protein] CTD PMID:23516405 NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
JBrowse link
G P2ry2 purinergic receptor P2Y2 decreases activity
multiple interactions
EXP
ISO
Suramin results in decreased activity of P2RY2 protein
Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RY2 protein]
CTD PMID:15654852 PMID:23516405 NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO JTE 013 promotes the reaction [Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin promotes the reaction [JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]] CTD PMID:18612546 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
increases expression
EXP
ISO
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of SHC1 protein]
Suramin results in increased expression of SHC1 mRNA; Suramin results in increased expression of SHC1 protein
CTD PMID:9710602 PMID:21778425 NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO Suramin inhibits the reaction [LMNA protein binds to and results in increased activity of SIRT1 protein]; Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
[Suramin results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol
CTD PMID:18482975 PMID:23217256 PMID:24252177 NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Tacr1 tachykinin receptor 1 multiple interactions EXP Suramin inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] CTD PMID:23666265 NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
JBrowse link
G Tnf tumor necrosis factor increases expression ISO Suramin results in increased expression of TNF protein CTD PMID:15914193 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] CTD PMID:18482975 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Vdr vitamin D receptor multiple interactions ISO Suramin inhibits the reaction [Estradiol results in increased expression of VDR protein] CTD PMID:15930183 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
JBrowse link
teriflunomide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO teriflunomide results in decreased phosphorylation of AKT1 protein CTD PMID:19174558 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO teriflunomide results in decreased expression of BCL2L1 mRNA CTD PMID:29427785 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO teriflunomide results in increased expression of BNIP3 mRNA CTD PMID:29427785 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
JBrowse link
G Ccna2 cyclin A2 increases expression ISO teriflunomide results in increased expression of CCNA2 protein CTD PMID:12181422 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO teriflunomide results in decreased expression of CCND2 protein CTD PMID:19174558 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Ccne1 cyclin E1 increases expression
decreases expression
ISO teriflunomide results in increased expression of CCNE1 protein
teriflunomide results in decreased expression of CCNE1 protein
CTD PMID:12181422 PMID:19174558 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Cdc25a cell division cycle 25A decreases expression ISO teriflunomide results in decreased expression of CDC25A protein CTD PMID:19174558 NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO teriflunomide results in increased expression of CDKN1A protein CTD PMID:12181422 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Chdh choline dehydrogenase decreases expression ISO teriflunomide results in decreased expression of CHDH mRNA CTD PMID:29427785 NCBI chr16:5,194,269...5,225,541
Ensembl chr16:5,194,269...5,225,537
JBrowse link
G Cxcr1 C-X-C motif chemokine receptor 1 decreases expression ISO teriflunomide results in decreased expression of CXCR1 mRNA CTD PMID:10076546 NCBI chr 9:75,768,124...75,771,122
Ensembl chr 9:75,766,770...75,771,084
JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 decreases expression ISO teriflunomide results in decreased expression of CYP24A1 mRNA CTD PMID:29427785 NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases activity
increases expression
ISO teriflunomide results in increased activity of CYP2B6 protein
teriflunomide results in increased expression of CYP2B6 mRNA
CTD PMID:30364229 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression
increases activity
ISO teriflunomide results in increased expression of CYP3A4 mRNA
teriflunomide results in increased activity of CYP3A4 protein
CTD PMID:30364229 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Ddx28 DEAD-box helicase 28 decreases expression ISO teriflunomide results in decreased expression of DDX28 mRNA CTD PMID:29427785 NCBI chr19:33,909,799...33,911,729
Ensembl chr19:33,909,801...33,911,742
JBrowse link
G Dhodh dihydroorotate dehydrogenase (quinone) multiple interactions
decreases expression
decreases activity
ISO
EXP
teriflunomide inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]]
teriflunomide results in decreased expression of DHODH mRNA
teriflunomide inhibits the reaction [DHODH protein results in increased metabolism of 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone]; teriflunomide inhibits the reaction [DHODH protein results in increased metabolism of 4,5-dihydroorotic acid]; teriflunomide inhibits the reaction [DHODH protein results in increased metabolism of Ubiquinone]; teriflunomide inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; teriflunomide inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]]
teriflunomide results in decreased activity of DHODH protein
CTD PMID:9776318 PMID:9802339 PMID:11248707 PMID:29427785 NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654
JBrowse link
G Egf epidermal growth factor multiple interactions ISO teriflunomide inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] CTD PMID:30364229 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO teriflunomide inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] CTD PMID:30364229 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 decreases phosphorylation ISO teriflunomide results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:19174558 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Fars2 phenylalanyl-tRNA synthetase 2, mitochondrial decreases expression ISO teriflunomide results in decreased expression of FARS2 mRNA CTD PMID:29427785 NCBI chr17:28,319,215...28,746,217
Ensembl chr17:28,319,280...28,746,337
JBrowse link
G Fasn fatty acid synthase decreases expression
multiple interactions
ISO teriflunomide results in decreased expression of FASN mRNA
[Colforsin co-treated with teriflunomide] results in increased expression of FASN mRNA
CTD PMID:30364229 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 increases expression
multiple interactions
ISO teriflunomide results in increased expression of G6PC1 mRNA
Colforsin inhibits the reaction [teriflunomide results in increased expression of G6PC1 mRNA]
CTD PMID:30364229 NCBI chr10:86,307,400...86,318,766 JBrowse link
G Gypa glycophorin A multiple interactions
increases expression
ISO Cytidine inhibits the reaction [teriflunomide results in increased expression of GYPA protein]; Uridine inhibits the reaction [teriflunomide results in increased expression of GYPA protein] CTD PMID:12181422 NCBI chr19:27,450,311...27,465,940 JBrowse link
G Hspa1l heat shock protein family A (Hsp70) member 1 like decreases expression ISO teriflunomide results in decreased expression of HSPA1L mRNA CTD PMID:29427785 NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
JBrowse link
G Il10ra interleukin 10 receptor subunit alpha increases expression ISO teriflunomide results in increased expression of IL10RA mRNA; teriflunomide results in increased expression of IL10RA protein CTD PMID:10076546 NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase multiple interactions ISO teriflunomide inhibits the reaction [TNF protein results in increased activity of LCK protein] CTD PMID:9973483 NCBI chr 5:141,888,319...141,916,992
Ensembl chr 5:141,888,326...141,903,794
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO teriflunomide inhibits the reaction [TNF protein results in increased activity of MAP2K1 protein] CTD PMID:9973483 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
JBrowse link
G Mtfr2 mitochondrial fission regulator 2 decreases expression ISO teriflunomide results in decreased expression of MTFR2 mRNA CTD PMID:29427785 NCBI chr 1:15,123,232...15,138,632 JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO Ceramides inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Hydrogen Peroxide inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Lipopolysaccharides inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Okadaic Acid inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]]; Tetradecanoylphorbol Acetate inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]] CTD PMID:9973483 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO teriflunomide inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein] CTD PMID:9973483 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression
affects localization
ISO teriflunomide results in increased expression of NR1I3 mRNA
teriflunomide affects the localization of NR1I3 protein mutant form
CTD PMID:30364229 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions
increases activity
ISO Mifepristone inhibits the reaction [teriflunomide results in increased activity of NR3C1 protein] CTD PMID:30364229 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
JBrowse link
G Oat ornithine aminotransferase increases expression ISO teriflunomide results in increased expression of OAT mRNA CTD PMID:29427785 NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 increases expression
multiple interactions
ISO teriflunomide results in increased expression of PCK1 mRNA
Colforsin inhibits the reaction [teriflunomide results in increased expression of PCK1 mRNA]
CTD PMID:30364229 NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases expression ISO teriflunomide results in decreased expression of RB1 protein CTD PMID:19174558 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Ceramides inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Hydrogen Peroxide inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Lipopolysaccharides inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Okadaic Acid inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein affects the localization of RELA protein]; teriflunomide inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]]; Tetradecanoylphorbol Acetate inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]] CTD PMID:9973483 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO teriflunomide results in decreased phosphorylation of RPS6KB1 protein CTD PMID:19174558 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Slc25a25 solute carrier family 25 member 25 increases expression ISO teriflunomide results in increased expression of SLC25A25 mRNA CTD PMID:29427785 NCBI chr 3:15,708,702...15,742,195
Ensembl chr 3:15,708,703...15,742,216
JBrowse link
G Tfb1m transcription factor B1, mitochondrial decreases expression ISO teriflunomide results in decreased expression of TFB1M mRNA CTD PMID:29427785 NCBI chr 1:44,115,240...44,161,737
Ensembl chr 1:44,119,166...44,161,709
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP teriflunomide inhibits the reaction [Carbon Tetrachloride results in increased secretion of TGFB1 protein] CTD PMID:15586409 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
teriflunomide inhibits the reaction [TNF protein affects the localization of RELA protein]; teriflunomide inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein results in increased activity of LCK protein]; teriflunomide inhibits the reaction [TNF protein results in increased activity of MAP2K1 protein]; teriflunomide inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; teriflunomide inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]]
teriflunomide inhibits the reaction [Carbon Tetrachloride results in increased secretion of TNF protein]
CTD PMID:9973483 PMID:15586409 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tp53 tumor protein p53 increases expression ISO teriflunomide results in increased expression of TP53 mRNA; teriflunomide results in increased expression of TP53 protein CTD PMID:10076546 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tuba1a tubulin, alpha 1A affects expression ISO teriflunomide affects the expression of TUBA1A mRNA CTD PMID:27015953 NCBI chr 7:130,113,214...130,116,880 JBrowse link
tranilast term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor increases response to substance
increases expression
multiple interactions
ISO AHR protein results in increased susceptibility to tranilast
tranilast results in increased expression of AHR mRNA
AHR protein promotes the reaction [tranilast results in increased expression of AHR mRNA]; AHR protein promotes the reaction [tranilast results in increased expression of CYP1A1 mRNA]; tranilast promotes the reaction [AHR protein binds to CYP1A1 promoter]
CTD PMID:25826687 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO tranilast results in decreased expression of CXCR4 mRNA CTD PMID:25826687 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases expression
ISO AHR protein promotes the reaction [tranilast results in increased expression of CYP1A1 mRNA]; tranilast promotes the reaction [AHR protein binds to CYP1A1 promoter] CTD PMID:25826687 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 affects expression ISO tranilast affects the expression of CYP1B1 mRNA CTD PMID:25826687 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO tranilast inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] CTD PMID:23769903 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
tyrphostin B42 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO tyrphostin B42 alone or co-treated with Nimesulide decreases expression of BIRC5 protein in esophagus squamous epithelium RGD PMID:25724470 RGD:127285656 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Casp3 caspase 3 multiple interactions ISO tyrphostin B42 co-treated with N-acetyl-L-cysteine inhibits the reaction [Ginkgoic acid increases cleavage of CASP3 protein in stomach] RGD PMID:32106377 RGD:127284886 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions ISO tyrphostin B42 co-treated with N-acetyl-L-cysteine inhibits the reaction [Ginkgoic acid decreases cleavage of CASP9 protein in stomach] RGD PMID:32106377 RGD:127284886 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Jak2 Janus kinase 2 decreases expression
multiple interactions
EXP
ISO
Turphostin B42 decreased expression of Jak2 mRNA in myofibroblasts
tyrphostin B42 inhibits the reaction [cisplatin increases expression of Jak2 mRNA in kidney]
tyrphostin B42 inhibits the reaction [selumetinib increases phosphorylation of JAK2 protein in colonic epithelium]
tyrphostin B42 decreases expression and phosphorylation of JAK2 protein in colonic epithelium
tyrphostin B42 co-treated with N-acetyl-L-cysteine inhibits the reaction [Ginkgoic acid increases phosphorylation of JAK2 protein in stomach]
RGD PMID:26385087 PMID:31250048 PMID:30706361 PMID:22050790 PMID:32106377 RGD:18337263, RGD:149735351, RGD:127285668, RGD:127285665, RGD:127284886 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
JBrowse link
G Mt-co2 mitochondrially encoded cytochrome c oxidase II decreases expression ISO Tyrphostin B42 alone or co-treated with Nimesulide decreases expression of MT-CO2 protein in esophagus squamous epithelium RGD PMID:25724470 RGD:127285656 Ensembl chr MT:7,006...7,689 JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO tyrphostin B42 co-treated with N-acetyl-L-cysteine inhibits the reaction [Ginkgoic acid increases phosphorylation of STAT3 protein in stomach] RGD PMID:32106377 RGD:127284886 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
WIN 18446 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 decreases activity EXP
ISO
N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine results in decreased activity of ALDH1A2 protein CTD PMID:12547725 PMID:30958995 NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
JBrowse link
G Hopx HOP homeobox multiple interactions ISO [nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in decreased expression of HOPX mRNA; [nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in decreased expression of HOPX protein CTD PMID:30995255 NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909
JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine inhibits the reaction [Vitamin A results in increased expression of HOXA1 mRNA] CTD PMID:23696197 NCBI chr 4:81,255,814...81,258,504
Ensembl chr 4:81,255,883...81,258,504
JBrowse link
G Id2 inhibitor of DNA binding 2 multiple interactions ISO [nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in increased expression of ID2 mRNA CTD PMID:30995255 NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
JBrowse link
G Pdpn podoplanin multiple interactions ISO [nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in decreased expression of PDPN mRNA; [nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in decreased expression of PDPN protein CTD PMID:30995255 NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
JBrowse link
ximelagatran term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G F2 coagulation factor II decreases cleavage
multiple interactions
ISO ximelagatran results in decreased cleavage of F2 protein
ximelagatran binds to and results in decreased activity of F2 protein
CTD PMID:15155122 PMID:16084352 PMID:16194202 PMID:17314111 NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19821
    chemical entity 19821
      atom 19819
        nonmetal atom 19707
          nitrogen atom 18765
            nitrogen molecular entity 18765
              organonitrogen compound 18538
                carboxamide 17299
                  secondary carboxamide 314
                    (-)-Jasmonoyl-L-isoleucine 0
                    (1R)-Hydroxy-(2R)-N-acetyl-L-cysteinyl-1,2-dihydronaphthalene 0
                    (1R)-N-Acetyl-L-cysteinyl-(2R)-hydroxy-1,2-dihydronaphthalene 0
                    (1S)-Hydroxy-(2S)-N-acetyl-L-cysteinyl-1,2-dihydronaphthalene 0
                    (2E,24R)-24-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-2-methylpentacos-2-enamide 0
                    (2R)-N-[(2S)-3,3-dimethyl-1-oxo-1-[[(1R)-1-phenylethyl]amino]butan-2-yl]-N'-hydroxy-2-[3-(3-methyl-4-phenylphenyl)propyl]butanediamide 0
                    (2S)-2-[[(2-chlorophenyl)-oxomethyl]amino]-3-methylbutanoic acid (3-cyano-4-imino-2-oxopentyl) ester 0
                    (2S)-2-[[(2-chlorophenyl)-oxomethyl]amino]-3-methylbutanoic acid (6-nitro-4H-1,3-benzodioxin-8-yl)methyl ester 0
                    (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-phenylacetic acid cyclopentyl ester 0
                    (2S)-2-[[(2S)-2-[(2S)-2-[[(2R)-2-amino-3-mercaptopropyl]amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                    (2S)-2-[[(2S)-2-[(2S,3R)-2-[(2-amino-3-mercaptopropyl)amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                    (2S)-2-[[2-[(2S,3S)-2-[[(2R)-2-amino-3-mercaptopropyl]amino]-3-methylpentoxy]-1-oxo-3-phenylpropyl]amino]-4-methylsulfonylbutanoic acid propan-2-yl ester 0
                    (2S)-2-[[[5-[[5-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentylamino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]propanoic acid tert-butyl ester 0
                    (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                    (2S)-2-acetamido-3-(1H-indol-3-yl)propanamide 0
                    (2S)-3-methyl-2-[[(3-methylphenyl)-oxomethyl]amino]butanoic acid (4-oxo-2-pyrimido[2,1-b][1,3]benzothiazolyl)methyl ester 0
                    (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                    (2S,3S,4R)-4-cyclopropyl-2-ethoxy-3-(3-hydroxypropyl)-N-prop-2-ynyl-3,4-dihydro-2H-pyran-6-carboxamide 0
                    (6R,7R)-7-[[(2R)-2-carboxy-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 0
                    (R)-N-trans-feruloyloctopamine 0
                    (Z)-N-cyclopropyl-11-methyldodec-2-enamide 0
                    (Z)-N-cyclopropyldodec-2-enamide 0
                    1-amino-15-oxo-4,7,10-trioxa-14-azaoctadecan-18-oic acid 0
                    1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-N-[4-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]-1,4-dihydroquinoline-3-carboxamide 0
                    2,2,2-trideuterio-N-[1,1,2,2-tetradeuterio-2-(5-hydroxy-1H-indol-3-yl)ethyl]acetamide 0
                    2,2,2-trifluoro-N-(2-methyl-8-quinolinyl)acetamide 0
                    2,2,2-trifluoro-N-(5-oxo-1-phenyl-4H-pyrazol-3-yl)acetamide 0
                    2,2,2-trifluoro-N-(8-hydroxyoctyl)acetamide + 0
                    2,2,2-trifluoro-N-[2-(1H-indol-3-yl)ethyl]acetamide 0
                    2,9-dideoxy-9-glutaramido-2,3-dehydo-N-acetylneuraminic acid 0
                    2-(1H-benzimidazol-2-yl)-N-(2-furanylmethyl)-3-[3-(trifluoromethyl)phenyl]-2-propenamide 0
                    2-(2,4-dioxo-1H-pyrimidin-6-yl)-N-[2-(4-morpholinyl)ethyl]acetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[2-[[3-(2-chlorophenyl)-1-oxoprop-2-enyl]amino]-4-thiazolyl]acetic acid ethyl ester 0
                    2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid 0
                    2-[[1-oxo-3-(4-pentylphenyl)prop-2-enyl]amino]benzoic acid 0
                    2-[[2-(3,4-dimethoxyanilino)-2-oxoethyl]thio]-3-pyridinecarboxylic acid propan-2-yl ester 0
                    2-[[2-cyano-3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]-4-phenyl-3-thiophenecarboxylic acid ethyl ester 0
                    2-[[3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic acid 0
                    2-[[3-(4-methoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic acid 0
                    2-[[oxo(thiophen-2-yl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid propan-2-yl ester 0
                    2-\{[2-(2-chlorophenyl)-2-hydroxyethyl]amino\}-N-[(2-fluorophenyl)methyl]acetamide 0
                    2-chloro-N-(4-fluorophenyl)-3-phenyl-2-propenamide 0
                    2-chloro-N-[2-[2-[(5-chloro-3-methyl-1-phenyl-4-pyrazolyl)methylidene]hydrazinyl]-2-oxoethyl]benzamide 0
                    2-chloro-N-[2-[2-[(5-nitro-2-thiophenyl)methylidene]hydrazinyl]-2-oxoethyl]benzamide 0
                    2-cyano-3-(1,3-dimethyl-2-oxo-5-benzimidazolyl)-N-(4-methoxyphenyl)-2-propenamide 0
                    2-cyano-3-(4,5-dimethoxy-2-nitrophenyl)-N-(2-oxolanylmethyl)-2-propenamide 0
                    2-cyano-N-(2-methoxyphenyl)-3-[5-nitro-2-(1-pyrrolidinyl)phenyl]-2-propenamide 0
                    2-cyano-N-(3-methylphenyl)-3-[4-(methylthio)phenyl]-2-propenamide 0
                    2-cyano-N-(4-ethoxyphenyl)-3-[3-methyl-4-(1-pyrrolidinyl)phenyl]-2-propenamide 0
                    2-cyano-N-[3-(1-imidazolyl)propyl]-3-(4-nitrophenyl)-2-propenamide 0
                    2-cyano-N-cyclohexyl-3-[4-(methylthio)phenyl]-2-propenamide 0
                    2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide + 0
                    2-methyl-N-(6-nitro-1,3-benzothiazol-2-yl)-3-phenyl-2-propenamide 0
                    3',4'-difluoro-N-\{4'-fluoro-6-[(3S)-pyrrolidin-3-yloxy][biphenyl]-3-yl\}-6-[(3S)-pyrrolidin-3-yloxy][biphenyl]-3-carboxamide 0
                    3-(1,3-benzodioxol-5-yl)-2-cyano-N-(4-hydroxyphenyl)-2-propenamide 0
                    3-(1,3-benzodioxol-5-yl)-N-(4-phenyl-2-thiazolyl)-2-propenamide 0
                    3-(1,3-benzodioxol-5-yl)-N-[2-(4-methylphenyl)-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]-2-propenamide 0
                    3-(1,3-benzodioxol-5-yl)-N-[2-[(4-chlorophenyl)methylthio]ethyl]-2-propenamide 0
                    3-(2,4-dimethylphenyl)-N-(thiophen-2-ylmethyl)-2-propenamide 0
                    3-(2-chloro-6-fluorophenyl)-N-pyridin-4-yl-2-propenamide 0
                    3-(2-chlorophenyl)-N-[4-(dimethylsulfamoyl)phenyl]-2-propenamide 0
                    3-(2-chlorophenyl)-N-pyridin-4-yl-2-propenamide 0
                    3-(2-nitrophenyl)-N-(3-pyridinyl)-2-propenamide 0
                    3-(3-anilino-3-oxoprop-1-enyl)-N-hydroxybenzamide 0
                    3-(4-chlorophenyl)-N-(3-methoxyphenyl)-2-propenamide 0
                    3-(4-fluorophenyl)-N-(6-methoxy-3-pyridinyl)-2-propenamide 0
                    3-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)-2-propenamide 0
                    3-(4-methoxyphenyl)-N-(11-oxo-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-2-yl)-2-propenamide 0
                    3-(4-tert-butylphenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-propenamide 0
                    3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide + 0
                    3-[3-[(2-bromo-4-chlorophenoxy)methyl]-4-methoxyphenyl]-N-[(1,3-dimethyl-4-pyrazolyl)methyl]-2-propenamide 0
                    3-amino-6-chloro-5-(dimethylamino)-N-(3-pyridinyl)-2-pyrazinecarboxamide 0
                    3-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide 0
                    3-bromo-N-\{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl\}-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide + 0
                    3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}-L-phenylalaninamide 0
                    3-methyl-2-[[oxo-(4-pentoxyphenyl)methyl]amino]butanoic acid 0
                    3-phenyl-N-(3-pyridinyl)-2-propenamide 0
                    3-phenyl-N-[2,2,2-trichloro-1-[[(8-quinolinylamino)-sulfanylidenemethyl]amino]ethyl]-2-propenamide 0
                    4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide 0
                    4-(2,6-difluorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide 0
                    4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide 0
                    4-[[(4-bromo-2-ethyl-3-pyrazolyl)-oxomethyl]amino]benzoic acid propan-2-yl ester 0
                    4-[[2-furanyl(oxo)methyl]amino]benzoic acid propan-2-yl ester 0
                    4-[[4-[2-cyano-3-(4-methoxyanilino)-3-oxoprop-1-enyl]-2-methoxyphenoxy]methyl]benzoic acid 0
                    4-amino-5-chloro-2-ethoxy-N-(\{4-[(4-fluorophenyl)methyl]morpholin-2-yl\}methyl)benzamide + 0
                    4-chloro-N-[1-[[5-(ethylthio)-1,3,4-thiadiazol-2-yl]amino]-3-methyl-1-oxobutan-2-yl]benzamide 0
                    4-chloro-N-[3-(3-methylanilino)-1-(5-nitro-2-furanyl)-3-oxoprop-1-en-2-yl]benzamide 0
                    4-hydroxyprotoasukamycin + 0
                    4-methylbenzenesulfonic acid [4-(3-amino-2-cyano-3-oxoprop-1-enyl)-2-methoxyphenyl] ester 0
                    5-(3-azidopropylamino)-5-oxopentanoic acid + 0
                    5-(4,6-dioxo-3-propan-2-yl-1-cyclohex-2-enylidene)-N-ethyl-4-[4-(4-morpholinylmethyl)phenyl]-2H-isoxazole-3-carboxamide 0
                    5-[[3-(1,5-dimethyl-4-pyrazolyl)-1-oxoprop-2-enyl]amino]-3-methylthiophene-2,4-dicarboxylic acid O2-ethyl ester O4-propan-2-yl ester 0
                    ANA-12 0
                    AZD-1152 + 0
                    AZD2858 0
                    AZD7545 0
                    AZT-1152 0
                    Arachidonoyl dopamine 0
                    Asn-Ile 0
                    BMS 195614 0
                    Butoctamide hydrogen succinate 0
                    CDN1163 0
                    CX-5461 0
                    Capsi-amide 0
                    Cuscuta propenamide 1 0
                    Cuscuta propenamide 2 0
                    Cyanthoate 0
                    Cys-Ser 0
                    DEL-22379 0
                    DPI2 0
                    EG00229 0
                    EI-1511-3 0
                    Fagaramide 0
                    GRL-0617 + 0
                    GSK-5498A 0
                    GSK343 2
                    JTE-607 free base 0
                    KOM70144 0
                    L-779976 0
                    L-803087 0
                    L-817818 0
                    LGK974 7
                    LSM-14399 0
                    LSM-17442 0
                    LSM-4709 0
                    LSM-9991 0
                    LimKi 3 0
                    MI-63 0
                    MK-8353 0
                    ML162 0
                    MMP-9-IN-1 0
                    N(1),N(8)-bis(caffeoyl)spermidine 0
                    N(1),N(8)-bis(coumaroyl)spermidine 0
                    N(1),N(8)-bis(sinapoyl)-spermidine 0
                    N(1),N(8)-bis-(dihydrocaffeoyl)spermidine 0
                    N(2)-(3-hydroxy-3-methylhexanoyl)-L-glutamine 0
                    N(2)-[(2E)-3-methylhex-2-enoyl]-L-glutamine 0
                    N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-3,3-dimethoxyalaninamide 0
                    N(2)-[4-(indol-3-yl)butanoyl]-L-glutamine 0
                    N(3)-fumaramoyl-(S)-2,3-diaminopropanoic acid 0
                    N(3)-fumaroyl-(S)-2,3-diaminopropanoic acid 0
                    N(4)-acetyl-2'-deoxycytidine 0
                    N(4)-acetylcytidine 0
                    N(6)-trifluoroacetyl-L-lysine 0
                    N,N',N''-tris(3-pyridyl)benzene-1,3,5-tricarboxamide 0
                    N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                    N,O-diacylethanolamine + 0
                    N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                    N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide + 2
                    N-(1-phenylethyl)acetamide + 0
                    N-(11-oxo-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-2-yl)-3-(3,4,5-trimethoxyphenyl)-2-propenamide 0
                    N-(2-anilino-2-oxoethyl)-2-methoxybenzamide 0
                    N-(2-hydroxydocosanoyl)eicosasphinganine 0
                    N-(2-hydroxyhexacosanoyl)phytosphingosine + 0
                    N-(3,7-dimethylocta-2,6-dien-1-yl)cyclopropanecarboxamide + 0
                    N-(3-anilino-3-oxo-1-phenylprop-1-en-2-yl)benzamide 0
                    N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide 0
                    N-(3-methoxyphenyl)-3-(4-nitrophenyl)-2-propenamide 0
                    N-(3-oxohexanoyl)homoserine lactone 0
                    N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                    N-(4-carboxy-4-oxobutanoyl)-L-ethylglycylglycine 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)-1-(N,N-dimethylglycyl)piperidine-4-carboxamide 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)-2-(4-methylpiperazin-1-yl)pyridine-4-carboxamide 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-carboxamide 0
                    N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-3-(4-fluorophenyl)-2-propenamide 0
                    N-(5-methyl-3-isoxazolyl)-3-(4-methylphenyl)-2-propenamide 0
                    N-(5-methyl-3-isoxazolyl)-3-phenyl-2-propenamide 0
                    N-([biphenyl]-2-yl)-3-cyclopentylpropanamide 0
                    N-(naphthyl)carboxamide + 1
                    N-(p-amylcinnamoyl)anthranilic acid 4
                    N-(saturated fatty acyl)ethanolamine + 14
                    N-(tert-butoxycarbonyl)-L-seryl-L-valyl-N-\{(2S,3E)-5-ethoxy-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl\}-L-leucinamide 0
                    N-(trifluoroacetyl)glycine 0
                    N-Methylolacrylamide 6
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R,6S)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S,6R)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S,6S)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S)-1-(1H-benzimidazol-2-ylamino)-3-methyl-1-oxobutan-2-yl]-3,5-dimethoxybenzamide 0
                    N-[(2S)-1-(1H-benzimidazol-2-ylamino)-3-methyl-1-oxobutan-2-yl]-3-methylbenzamide 0
                    N-[(2S)-2-aminobutanoyl]glycine 0
                    N-[(2S)-3-cyclohexyl-1-oxo-1-(\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}amino)propan-2-yl]-1H-indole-2-carboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R,6S)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-[[(3S)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(4-chlorophenyl)methyl]-2-(2,4-dioxo-1H-pyrimidin-6-yl)acetamide 0
                    N-[(6-hydroxyindol-3-yl)acetyl]phenylalanine 0
                    N-[1-(2,5-dimethoxyphenyl)-3-[2-[(5-methyl-2-thiophenyl)methylidene]hydrazinyl]-3-oxoprop-1-en-2-yl]benzamide 0
                    N-[1-[(2,6-dimethylanilino)-oxomethyl]cyclopentyl]-N-(phenylmethyl)-4-(1-tetrazolyl)benzamide 0
                    N-[1-[(4-chlorophenyl)methyl]-4-pyrazolyl]-2-pyrazinecarboxamide 0
                    N-[2-(2-methoxyphenoxy)ethyl]-3-(4-methoxyphenyl)-2-propenamide 0
                    N-[2-(3,4-dihydroxyphenyl)ethyl]-9-octadecenamide 0
                    N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide 0
                    N-[2-[3-(dimethylamino)propylthio]phenyl]-3-phenyl-2-propenamide 0
                    N-[2-chloro-5-(trifluoromethyl)phenyl]-2-cyano-3-[3-methoxy-4-[2-oxo-2-[3-(trifluoromethyl)anilino]ethoxy]phenyl]-2-propenamide 0
                    N-[3-(4-\{[1-(5-chloro-2,4-dimethoxyanilino)-1-oxopropan-2-yl]sulfanyl\}anilino)-3-oxo-1-phenylprop-1-en-2-yl]benzamide 0
                    N-[3-(4-hydroxyanilino)-3-oxo-1-pyridin-4